Omniflox was approved to treat lower respiratory tract infections, genital and urinary infections like prostatitis, and skin infections in the United States by the [[Food and Drug Administration]] in January 1992. Severe adverse reactions, including [[allergic reaction]]s and [[hemolytic anemia]],<ref>{{Cite journal|title=History of quinolones and their side effects.|journal=Chemotherapy|volume=47 Suppl 3|issue=|pages=3–8; discussion 44–8|doi=10.1159/000057838|pmid=11549783|last1=Rubinstein|first1=E.}}</ref> developed in over 100 patients during the first four months of its use, leading to three patient deaths. Abbott withdrew the drug from sale in June 1992.
